Friday, December 3, 2021

The Responsiveness of Gait and Balance Outcomes to Disease Progression in Friedreich Ataxia

›
Sarah C. Milne, Seok Hun Kim, Anna Murphy, Jane Larkindale, Jennifer Farmer, Ritchie Malapira, Mary Danoudis, Jessica Shaw, Tyagi Ramakrishn...
Wednesday, December 1, 2021

Nuclear Factor Erythroid-Related Factor 2 Signaling in the Neuropathophysiology of Inherited Metabolic Disorders

›
Bianca Seminotti1, Mateus Grings, Paolo Tucci, Guilhian Leipnitz1, Luciano Saso; Front. Cell. Neurosci., 26 November 2021 doi:10.3389/fncel....
Monday, November 29, 2021

Source of medical information and behavioral seeking patterns in patients affected with Friedreich's ataxia and their caregivers: a survey study

›
Miele G, Lavorgna L, De Mercanti SF, Iudicello M, Abbadessa G, Matta M, Bonavita S, Clerico M.; Neurol Sci. 2021 Nov 28. doi: 10.1007/s10072...
Tuesday, November 23, 2021

Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia

›
Emanuele Monda, Michele Lioncino, Marta Rubino, Silvia Passantino, Federica Verrillo, Martina Caiazza, Annapaola Cirillo, Adelaide Fusco, Fr...
Monday, November 22, 2021

Cellular pathophysiology of Friedreich's ataxia cardiomyopathy

›
Jarmon G. Lees, Marek Napierala, Alice Pébay, Mirella Dottori, Shiang Y. Lim; International Journal of Cardiology, 2021, doi:10.1016/j.ijcar...
Friday, November 19, 2021

Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress

›
Published : Friday, November 19, 2021, ACROFAN=Businesswire.  XCUR-FXN–Friedreich’s Ataxia Exicure remains committed to maintaining its dev...

Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia

›
November 18, 2021, PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, today announced the U.S. Food and Drug Administration (“FDA”) has g...
Thursday, November 18, 2021

Body Mass Index and Height in Friedreich Ataxia What Do We Know?

›
Sylvia M. Boesch, Elisabetta Indelicato; Neurol Genet Dec 2021, 7 (6) e637; DOI: 10.1212/NXG.0000000000000637  In this issue of Neurology® G...
Tuesday, November 16, 2021

STEALTH BIOTHERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

›
11/12/2021. MarketScreener. Friedreich's ataxia. The investigator is awaiting Institutional Review Board approval of the planned Phase 2...

Larimar expects to initiate its Jive open-label extension and pediatric multiple ascending dose trials in the first half of next year.

›
BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”), a clinical-stage biotechnology company focused o...